Macquarie Group
CPRX

Macquarie Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Macquarie Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-761,740
Closed -$15M – 1000
2025
Q3 		$15M Sell
761,740
-143,545
-16% -$2.95M 0.02% 728
2025
Q2 		$19.6M Sell
905,285
-29,327
-3% -$692K 0.02% 673
2025
Q1 		$22.7M Buy
934,612
+251,960
+37% +$5.67M 0.03% 629
2024
Q4 		$14.2M Buy
+682,652
New +$14.7M 0.02% 733
2022
Q4 		– Sell
-186,900
Closed -$2.42M – 1836
2022
Q3 		$2.42M Sell
186,900
-2,011
-1% -$23.8K ﹤0.01% 1164
2022
Q2 		$1.32M Hold
188,911
– – ﹤0.01% 1410
2022
Q1 		$1.57K Sell
188,911
-600
-0.3% -$4.24K ﹤0.01% 1441
2021
Q4 		$1.28M Sell
189,511
-23,495
-11% -$154K ﹤0.01% 1505
2021
Q3 		$1.13M Buy
213,006
+2,200
+1% +$12K ﹤0.01% 1557
2021
Q2 		$1.21M Buy
210,806
+85,216
+68% +$440K ﹤0.01% 1559
2021
Q1 		$579K Sell
125,590
-9,237
-7% -$36.7K ﹤0.01% 1503
2020
Q4 		$451K Hold
134,827
– – ﹤0.01% 1468
2020
Q3 		$401K Buy
134,827
+112,073
+493% +$438K ﹤0.01% 1449
2020
Q2 		$105K Buy
+22,754
New +$102K ﹤0.01% 1736
2018
Q1 		– Sell
-2,100
Closed -$8K – 2203
2017
Q4 		$8K Buy
+2,100
New +$6.94K ﹤0.01% 2303

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's CPRX Position: Q4 2025 in Review

Macquarie Group sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 761,740 shares — an estimated $15M sold.

Macquarie Group first reported a position in CPRX in Q4 2017 and held it in 15 quarters. The position peaked at $22.7M in Q1 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Macquarie Group reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 761,740 Catalyst Pharmaceutical shares in Q4 2025, an estimated $15M.
  • Macquarie Group first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 15 quarters.
  • Macquarie Group's Catalyst Pharmaceutical position peaked at $22.7M in Q1 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.